Stocks-SWTX-SpringWorks Therapeutics Inc

SWTX SpringWorks Therapeutics Inc

27.25 0.09 (0.33%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Stocks-SWTX-SpringWorks Therapeutics Inc
SWTX SpringWorks Therapeutics Inc
Invest

Performance

0% Past Week
Market Cap
1.7B
Day’s Range
26.46
-
28.14
52W Range
19.20
-
39.69
Volume (3M)
682.25K
Price-Earnings Ratio
-5.3
Revenue
-
Pinned Post
Edited
Genome Engineering
United Kingdom
3 days ago
FDA Accepts GSK Supplemental Application for Jemperli Plus Chemo 👉 $GSK (GlaxoSmithKline plc ADR) announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult... Show More
Like CommentShare
null
.
Top Discussions

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutics enterprise that acquires, develops, and markets medicines for patients within the United States. These therapies target rare diseases and cancers with unmet medical need. The company is headquartered in Stamford, Connecticut, and was established in 2017. The SWTX ticker identifies SpringWorks on the NASDAQ GS. Remain updated on SWTX share price developments by adding this item to your watchlist.
227
Employees
Stamford, Connecticut, US
HQ
2017
Founded
Saqib Islam
CEO
Show More
Med TechNASDAQ

Upcoming Earnings

3
AUG
REPORTS
SpringWorks Therapeutics Inc Q2 2023 earnings report is expected to be released before market open

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
51
Medium
Industry 
Avg. 48 
34
Environment
40
Social
70
Governance

People Also Bought